SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after releasing positive interim results from a pivotal trial for its ANKTIVA bladder cancer treatment, indicating superior efficacy for first-line use, as the community discusses its transformative market potential and significant short interest, alongside strategic moves by its founder into radioligand therapy supply.

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare is trending due to a recently enacted 1-for-30 reverse stock split, which has sparked intense debate among investors. While many view the move as a sign of management's incompetence and predict further dilution, others believe it strategically cleans up the capital structure, enables Nasdaq compliance, and positions the company for significant catalysts, including its de-risked and Fast-Tracked drug pipeline.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is rallying as the community intently focuses on whether the company will decline to match a recently deemed superior offer for Warner Bros. Discovery, with many investors hoping this avoids substantial debt and regulatory obstacles, potentially triggering further upside as the crucial decision looms.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as a major strategic shift towards AI and high-performance computing data centers, driven by new partnerships and acquisitions, is generating intense community discussion and speculation about a significant short squeeze, largely overshadowing recent disappointing financial results.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending after its latest earnings report revealed record annual revenue, a GAAP profit, and robust 2026 guidance, sparking strong bullish sentiment among investors. The community is actively debating the potential for a short squeeze given high short interest, though some members remain cautious about the company's long-term profitability trajectory.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab's Q4 earnings report is driving conversation with strong revenue growth and backlog, though the Neutron rocket's first launch is now targeted for late 2026. Community discussion highlights numerous new launch contracts and strategic acquisitions, particularly strengthening RKLB's position in the defense sector and solidifying its role as a diversified space systems provider.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending as its WVE-007 obesity treatment garners significant community excitement for its differentiated profile, showing fat loss with muscle preservation and potential for infrequent dosing, especially following recent setbacks for competing GLP-1 therapies. Analysts and investors are closely watching upcoming presentations and financial results, fueling M&A speculation for its innovative RNAi platform in a rapidly expanding market.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending as Netflix walks away from its acquisition bid after Paramount Skydance's offer was deemed superior, with the community largely praising Netflix's strategic move to collect a significant breakup fee, while WBD investors anticipate a higher payout from Paramount despite new debt concerns for the acquirer.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending due to the final investment approval for its Romanian SMR project, bolstering the narrative that small modular reactors are essential for increasing global power demands, especially from AI data centers. The community is actively debating this positive catalyst against recent selling pressure from a major shareholder and ongoing class-action lawsuit allegations, leading to high volatility.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is drawing significant attention due to its innovative partnership with Framework Ventures to tokenize mortgages, leveraging a stablecoin ecosystem and its AI-powered Tinman platform to offer lower rates. Community discussion highlights the potential for a short squeeze driven by Framework's impending large share acquisitions and growing institutional interest, signaling a disruptive shift in the mortgage industry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Brokers Set Expectations for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Iovance Biotherapeutics in a research report issued to clients and...

Barclays Boosts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $11.00

Barclays upped their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Wednesday...

IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress

Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.

Iovance Biotherapeutics (NASDAQ:IOVA) Sees Strong Trading Volume Following Earnings Beat

Iovance Biotherapeutics (NASDAQ:IOVA) Sees Large Volume Increase on Strong Earnings...

Chardan Capital Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price

Chardan Capital lowered their target price on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a "buy" rating on the stock in a research note on Wednesday...

Iovance Biotherapeutics (NASDAQ:IOVA) Raised to Market Outperform at Citizens Jmp

Citizens Jmp upgraded Iovance Biotherapeutics from a "market perform" rating to a "market outperform" rating and set a $5.00 price target on the stock in a research report on Wednesday...

<ul class="summary-bullets"><li>Chardan reiterated a ‘Buy’ rating and sees 323% upside, despite trimming its price target to $16 from $17.</li><li>Q4 margins hit a record high, with gross margin climbing to 50% from 43% in Q3, which the interim CEO said was Iovance’s “best ever” performance.</li><li>Pipeline momentum strengthened, with FDA Fast Track designation for Lifileucel in nonsquamous lung cancer.</li></ul>Shares of Iovance Biotherapeutics, Inc. (IOVA) posted their best session in two years on Tuesday after the company reported record fourth-quarter (Q4) margins, with investor sentiment buoyed by an analyst rating that implied more than 300% upside from current levels.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> jumped over 30% to $3.78 in Tuesday’s regular session, and added another 0.7% in extended trading.&nbsp;&nbsp;<h2 class="st-heading-2">Chardan Sees Huge Upside For IOVA</h2>On Tuesday, Chardan lowered its price target on Iovance to $16 from $17, implying a 323% upside from current levels, while retaining a ‘Buy’ rating.&nbsp;The brokerage attributed the Q4 margin rise to operational optimization and said further improvements are expected through 2026 as the company internalizes manufacturing of Lifileucel, its immune cell therapy for solid tumors, at its iCTC facility and optimizes research and development spending. It added that Iovance’s pipeline continues to advance, with early data in soft tissue sarcomas “looking encouraging.”<h2 class="st-heading-2">Amtagvi Drives Strong Q4 Revenue Surge</h2>Iovance reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-iova-stock-gain-pre-market-today/cZRvxIHR4Cc">Q4 revenue</a> of $86.7 million, beating analyst expectations of $81 million, while posting a Q4 loss of $0.18 per share, in line with estimates.Q4 total product revenue rose about 30% from the previous quarter to $87 million, led by about $65 million in U.S. Amtagvi revenue, a cell-based therapy for advanced melanoma, and $22 million from global Proleukin sales, a drug that helps activate the immune system during treatment.Gross margin from cost of sales climbed to 50%, up from 43% in the prior quarter, marking the company’s “best ever” margin performance, according to interim CEO Frederick Vogt, as said on the earnings call.For full-year 2025, Iovance reported total product revenue of about $264 million, coming in within its guidance range of $250 million to $300 million. The company ended the year with $303 million in cash, which is expected to fund operations into the third quarter of 2027.<h2 class="st-heading-2">CEO Sees “Remarkable” Revenue Growth In 2026</h2>Vogt said Iovance achieved its 2025 guidance range in its first full year of commercial launch, driven by rising demand for Amtagvi. On the earnings call, he said the company expects “remarkable revenue growth” in 2026 and sees potential for Amtagvi and Proleukin to generate more than $1 billion in peak U.S. sales.The company noted Amtagvi’s approval in Canada and pending regulatory decisions in the U.K. and Australia in the first half of 2026, with Switzerland targeted for the first half of 2027. Iovance is also working with European regulators to resubmit a marketing authorization application in 2026.<h2 class="st-heading-2">FDA Fast Track Granted For Lifileucel In Lung Cancer</h2>Iovance said Lifileucel has received Fast Track Designation from the FDA for previously treated nonsquamous non-small cell lung cancer, with interim data showing a 26% objective response rate and durability extending beyond 25 months. The company expects to complete enrollment in 2026 and to target an accelerated launch in the second half of 2027.Separately, the company announced positive early data in advanced soft-tissue sarcomas, where Lifileucel delivered a 50% confirmed response rate in an initial cohort of heavily pretreated patients. Iovance plans to initiate a single-arm registrational trial in the second quarter of 2026 and engage with regulators on an accelerated approval pathway.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IOVA was ‘extremely bullish’ amid a 550% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/iova_ss_png_a21e8bee3a.webp" alt="iova ss.png" width="970" height="142"><figcaption>IOVA sentiment and message volume as of February 25 | Source: Stocktwits</figcaption></figure>One user said, “potentially this could help Q1 margins go up further. If they can reach somewhere around 60%, it’ll be great progress towards profitability.”<stembedurl>https://stocktwits.com/ap20190829/message/645806810</stembedurl>Another user said, “THIS IS A 10/ share stock no doubt. You still have time to get it and make hay.”<stembedurl>https://stocktwits.com/ScottyG305/message/645801421</stembedurl>IOVA stock has surged 38% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

Shares of Iovance Biotherapeutics, Inc. (IOVA) posted their best session in two years on Tuesday after the company reported record fourth-quarter (Q4) margins

Equity

Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized.

Top Penny Stocks To Add to Your Watchlist - February 24th

Larimar Therapeutics, Iovance Biotherapeutics, and Mana Capital Acquisition are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced...

Best Biotech Stocks To Research - February 24th

ImmunityBio, Vir Biotechnology, Larimar Therapeutics, Iovance Biotherapeutics, Danaher, Moderna, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener...

$IOVA Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.18 up 30.77% YoY
• Reported revenue of $86.71M up 17.66% YoY
• Iovance anticipates continued significant operating losses and expenses for commercial activities and clinical programs, requiring additional financing for future operations beyond its current capital, despite sufficient funds for the next twelve months.

Stocktwits

Iovance Biotherapeutics Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.18 up 30.77% YoY
• Reported revenue of $86.71M up 17.66% YoY
• Iovance anticipates continued significant operating losses and expenses for commercial activities and clinical programs, requiring additional financing for future operations beyond its current capital, despite sufficient funds for the next twelve months.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Early-stage data in soft tissue sarcoma showing a 50% confirmed Objective Response Rate (ORR) has traders excited, significantly surpassing historical benchmarks of less than 5%.

Traders are eyeing a potential short squeeze with reported short interest soaring to 131 million shares, pushing many short positions underwater.

Anticipation is building for the IOV-LUN-202 lung cancer trial data and potential sBLA filing, seen as a crucial catalyst to unlock a vastly larger market opportunity.

Investors are eagerly awaiting updated 2026 revenue guidance from management, with speculation it is strategically withheld for a major positive announcement.

Many users believe the stock is significantly undervalued compared to peers, citing impressive forecasted earnings and revenue growth, and improving margins towards cash flow neutrality.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.14	--	--	N/A
Q4 '25	-$0.17	-$0.18	-2.90%	MISSED
Q3 '25	-$0.26	-$0.25	2.98%	BEAT
Q2 '25	-$0.28	-$0.33	-16.70%	MISSED
Q1 '25	-$0.24	-$0.36	-48.93%	MISSED

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest IOVA News

IOVAIovance Biotherapeutics Inc